Lundbeckfonden Ventures nyheder

Lundbeckfond Ventures is LFÍ Life Science Investments new name
Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, announces it has successfully raised £18 million in new funding
Mette Kirstine Agger appointed Head of LFI Life Science Investments
1 61 62 63

Lundbeckfonden Ventures


First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis
17. februar 2020
Spero Therapeutics Announces Commencement of Rights Offering
11. februar 2020
Spero Therapeutics Announces Exercise of $15.9 Million Option by BARDA for Tebipenem HBr Development
5. februar 2020